Results
|
|
1.
|
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. MedStar authors:
Year: 2019
Citation: - The Lancet Diabetes & Endocrinology. 7(8):596-605, 2019 08.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Gonzalez-Galvez G, Gron R, Halladin N, Haluzik M, Jermendy G, Kok A, Orsy P, Sabbah M, Sesti G, Silver R
|
|
|
2.
|
Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. MedStar authors:
Year: 2019
Citation: - Diabetes Technology & Therapeutics. 21(5):273-285, 2019 May.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bailey TS, Bergenstal RM, Brazg RL, Calibra Study Group, Dreon DM, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Levy BL, Naik RG, Peyrot M, Ramtoola S, Rosenstock J, Serusclat P, Shearer DM, Weinstock RS, Zraick V
|
|
|
3.
|
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. MedStar authors:
Year: 2016
Citation: - Journal of Clinical Endocrinology & Metabolism. 101(4):1754-61, 2016 Apr
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Aroda VR, Bray GA, Crandall JP, Diabetes Prevention Program Research Group, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Schade DS, Temprosa MG, White NH
|
|
|
4.
|
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. MedStar authors:
Year: 2018
Citation: - The Lancet Diabetes & Endocrinology. 6(4):275-286, 2018 04.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andreassen C, Aroda VR, Lingvay I, Ludemann J, Navarria A, Pratley RE, SUSTAIN 7 investigators, Viljoen A
|
|
|
5.
|
Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer. MedStar authors:
- Bikas, Athanasios
- Burman, Kenneth D
- Desale, Sameer
- Mete, Mihriye
- Van Nostrand, Douglas
- Wartofsky, Leonard
Year: 2016
Citation: - Thyroid. 26(2):280-6, 2016 Feb
Institution:
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
All authors: - Bikas A, Burman KD, Desale S, Jensen K, Mete M, Patel A, Van Nostrand D, Vasko V, Wartofsky L
|
|
|
6.
|
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Endocrinology & Metabolism. 100(5):1855-62, 2015 May.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Adam KP, Banerji M, Bray GA, Buchanan TA, Clement SC, Cobb JE, DeFronzo RA, Ferrannini E, Gall W, George T, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|
|
|
7.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
|
8.
|
Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. MedStar authors:
- Burman, Kenneth D
- Klubo-Gwiezdzinska, Joanna
- Mete, Mihriye
- Wartofsky, Leonard
Citation: - Journal of Clinical Endocrinology & Metabolism. 98(8):3269-79, 2013 Aug.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bauer A, Burman KD, Costello J Jr, Jensen K, Klubo-Gwiezdzinska J, Mete M, Patel A, Vasko V, Wartofsky L
|
|
|
9.
|
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(6):1706-11, 2014 Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|
|
|
10.
|
Implications of remote monitoring Technology in Optimizing Traditional Self-Monitoring of blood glucose in adults with T2DM in primary care. MedStar authors:
- Magee, Michelle
- Montero, Alex R
- Nassar, Carine M
- Youssef, Gretchen A
Year: 2021
Citation: - BMC Endocrine Disorders. 21(1):222, 2021 Nov 10.
Institution:
- MedStar Diabetes Institute
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Medline publication type:
All authors: - Gann K, Magee MF, Montero AR, Nassar CM, Toro-Tobon D, Youssef GA
|
|
|
11.
|
|
|
|
12.
|
Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. MedStar authors:
Year: 2019
Citation: - Journal of the American College of Cardiology. 73(16):2049-2058, 2019 04 30.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Berman DS, Boden WE, COURAGE Trial Research Group, Hartigan PM, Kostuk WJ, Mancini GBJ, Maron DJ, Spertus JA, Teo KK, Weintraub WS
|
|
|
13.
|
|
|
|
14.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
15.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
|
16.
|
Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(9):2622-31, 2014 Sep.
All authors: - Diabetes Prevention Program Research Group, Goldberg RB, Hamman RF, Horton E, Kitabchi A, Larkin M, Mather KJ, Montez MG, Orchard TJ, Perreault L, Temprosa M, Thayer D
|
|
|
17.
|
Synergy to reduce emergency department visits for uncontrolled hyperglycemia. MedStar authors:
- Dubin, Jeffrey S
- Fokar, Ali
- Magee, Michelle F
- Nassar, Carine M
- Sharretts, John M
- Smith, Mark S
Citation: - Diabetes Educator. 39(3):354-64, 2013 May-Jun.
Institution:
- MedStar Diabetes Institute
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Department:
- Emergency Medicine
- Medicine/Endocrinology
- MedStar Diabetes Institute
Medline publication type:
- Evaluation Studies
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Copeland J, Dubin JS, Fokar A, Magee MF, Nassar CM, Sharretts JM, Smith MS
|
|
|
18.
|
Arsenic exposure, arsenic metabolism, and incident diabetes in the strong heart study. MedStar authors:
- Howard, Barbara V
- Umans, Jason G
Citation: - Diabetes Care. 38(4):620-7, 2015 Apr.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Best LG, Francesconi KA, Goessler W, Gribble MO, Guallar E, Howard BV, Kuo CC, Lee E, Navas-Acien A, Umans JG
|
|
|
19.
|
|
|
|
20.
|
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. MedStar authors:
Year: 2013
Citation: - Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D
|
|
|
21.
|
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). MedStar authors:
Year: 2012
Citation: - The International Journal of Cardiovascular Imaging. 28(3):455-65, 2012 Mar.
Institution: - MedStar Health Research Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - APPROACH study group, Brugaletta S, Garcia-Garcia HM, Garg S, Huang C, Kolatkar NS, Kravitz BG, Miller DM, Morocutti G, Nesto RW, Ratner RE, Serruys PW
|
